MedCity News

JANUARY 13, 2025

Johnson & Johnsons agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared first on MedCity News.

Prospecting 282

Prospecting Biopharma Pharma 282

PharmaVoice

JANUARY 13, 2025

The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.

FDA 147

FDA 147

PharmaTimes

JANUARY 13, 2025

Survey finds AI to enhance productivity and cut costs in the next 12 months

Pharmaceutical 116

Pharmaceutical 116

PharmaVoice

JANUARY 13, 2025

Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.

Manufacturing 147

Manufacturing 147

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

Sales

PharmaTimes

JANUARY 13, 2025

Companies aim to provide new treatments for inflammatory conditions

Pharma 113

Pharma 113

pharmaphorum

JANUARY 13, 2025

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103

103

European Pharmaceutical Review

JANUARY 13, 2025

GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.

Biopharma 59

Biopharma Safety Patients Management 59

pharmaphorum

JANUARY 13, 2025

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

Marketing 98

Marketing 98

PharmaTech

JANUARY 13, 2025

Pharmaceutical Technology chats about the increasing prevalence of challenging APIs in the development pipeline and the hurdles facing formulators and manufacturers as a result of this trend with Jens Schmidt from Lonza.

Manufacturing 64

Manufacturing Pharmaceutical 64

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

pharmaphorum

JANUARY 13, 2025

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

96

96

PharmaTech

JANUARY 13, 2025

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telixs portfolio, along with other novel targets currently in the discovery stage.

59

59

pharmaphorum

JANUARY 13, 2025

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by Reuters to be worth around $442 million. Biogen has a longstanding alliance in place with Sage and co-markets Zurzuvae (zuranolone), which is FDA-approved for post-partum depression (PPD).

FDA 105

FDA Marketing 105

Pharmaceutical Technology

JANUARY 13, 2025

After selling its PI3K program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotechs current shareholders.

59

59

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

Sales

pharmaphorum

JANUARY 13, 2025

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

75

75

Pharmaceutical Technology

JANUARY 13, 2025

CEO Albert Bourla expressed modest optimism for Pfizers 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

59

59

pharmaphorum

JANUARY 13, 2025

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

59

59

PharmaTech

JANUARY 13, 2025

This is the latest facility launch for BioDuro, following a kilogram laboratory and compound management center, both on the same site, in October 2024.

Management 59

Management 59

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

Pharmaceutical Technology

JANUARY 13, 2025

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvaes launch in postpartum depression.

59

59

Pharmaceutical Commerce

JANUARY 13, 2025

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

FDA 59

FDA 59

Pharmaceutical Technology

JANUARY 13, 2025

Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latters STAT6 programmes.

Pharma 59

Pharma 59

Pharmaceutical Commerce

JANUARY 13, 2025

The latest news for pharma industry insiders.

Pharma 59

Pharma Healthcare Healthcare 59

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Pharmaceutical Technology

JANUARY 13, 2025

IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Leads 59

Leads Patients 59

Pharmaceutical Commerce

JANUARY 13, 2025

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

Pharma 59

Pharma 59

Pharmaceutical Technology

JANUARY 13, 2025

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

59

59

Pharmacy Times

JANUARY 13, 2025

The new Medicare cap limits out-of-pocket drug costs to $2000 annually.

Patients 55

Patients 55

Advertiser: ZoomInfo

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

Prospecting

Pharmaceutical Technology

JANUARY 13, 2025

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Medicine 59

Medicine 59

PharmaTimes

JANUARY 13, 2025

Companies aim to provide new treatments for inflammatory conditions

Pharma 52

Pharma 52

Pharmaceutical Technology

JANUARY 13, 2025

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.

59

59